No evidence indicated that the use of TNF-α inhibitors influenced the risk of serious infections, malignant tumors.<h4>Conclusion</h4>In conclusion, we regard etanercept monotherapy as the optimal choice for RA patients in clinical practice when the efficacy is similar. The gene discussed is TNF; the disease is infection.